MicroRNAs (mirNAs) have garnered tremendous interest in cancer biology research in the recent decade. mirNAs are a group of short non-coding RNAs,20-24 nucleotides in length, thatare found in animals and plants.Theycan reduce the expression of genes involved in numerous vital cell processes. Recent evidences indicate a key role played by mirNAs in the initiation and development of human carcinogenesis. These function including: the regulation of oncogenes, tumor suppressor genes, and several tumor-associated genes to that of processes such as cell proliferation, apoptosis, and angiogenesis. Clinical trials aimed at improving mirNA profiling for clinical diagnosis and prognosis of different disorders are now underway. In this review, we have summarized the physiological role of mirNAs and theirdiagnostic and therapeutic potential inclinical assessment.
Research in Molecular Medicine (RMM)
Hossein Javdani and Negin Parsamanesh frame of the aim mRNA are involved in the recognition process across the genome ( Figure 1 ) (18) (19) (20) . Reports estimate that about 30%of the human genomeis controlled by mirNAs and this makes mirNAs one of the biggest groups of target specific regulatory molecules in the body (21) . MicroRNA biogenesis and regulation. The pri-mirNA is capped, polyadenylated, and then cleaved in the nucleus and identified as a precursor mirNA (pre-mirNA). Then, Dicer (RNase III enzyme) cleaves the double stranded mature RNA duplex by RISCs and guides the translation of mature mirNA.
A Potential Role for MicroRNA Expression in Cancer
Most types of cancers have characteristics including the lack of cellular identity, enhancement of proliferation ability, and loss of the cell death regulatory system (22) (23) (24) .Studies carried out in different organisms have indicated that mirNAs are involved in several of these cellular processes, suggesting that they play a critical role in carcinogenesis. Several reports have firmly established that mirNAs are expressed in cancer tissues and normal. Further, that they are located in tumor-associated genomic sites or in fragile regions (22) . Amplification, deletion, and translocation of mirNA genesin tumor cells may lead to mirNA copy number variation (25) . Research has demonstrated an absence of the mir-16 and mir-15a genes in the 13q14 chromosomal region of B-cell chronic lymphocytic leukemia (B-CLL) patients (26) . In lung cancer, the genes mir-143 and mir-145 in the 5q33 region are mostly omitted leading to reducedmirNA expression (27) .However, mir-17-92 gene amplification was found in lung tumor and B-cell lymphomas (BCL).In addition, over expression of this gene cluster was also observed in T-cell acute lymphoblastic leukemia (T-ALL) (28) cancer with a remarkable prognostic potential on the survival of surgically treated cases and was implicated in reduction of genomic instability and transformation inhibition (36, 37) . Argonaute genes such as AGO3, AGO1, and AGO4 are located in 1p34-35 and were found to be mutated in Wilms tumors and correlated with neuroectodermal tumors (38) .Further research indicated that mirNA inhibition could be essential in designingdrugsfor disorders such as tumors.
mirNA Approach in Cancer Diagnosis and Treatment
Various studies have demonstrated the significant roles played by mirNAs in tumorige- Table   1 shows microRNA abnormality in tumorigenesis) (44) .In addition, circulating mir-141 and mir-375 levels were found to be associated with metastatic prostate cancer and could be used as a prognostic biomarker. Bianchi 
Genetic variation
Since 2004, different evidences have demonstrated that about half of the mirNAs are found in fragile sites and tumor susceptibility regions (47) . Different studies involving mapping repetitive sequences, breakpoints and CpG islands have been performed to confirm the association of mirNA genes with fragile sites (48) . In addition, certain mutations that result in changes inmirNA sequences might be involved in down-regulation of cancer suppressor genes and lead to oncogenesis. Thus, several genetic polymorphisms influence mirNA molecular pathways and processing of mirNA precursors (49).
Epigenetic alteration
Aberrant epigenetic processes a well-known feature of malignant cells and possibly happens in primary stage of cell cycles. Epigenetic alterations leading to DNA methylation and histone modification have been noted in particular cancers (49) .Most studies have utilized chromatin remodeling therapy to address epigenetic change of microRNAs (50).
Conclusion
Diagnostic, predictive and therapeutic potentials of mirNAs have been significantly determined by various research studies. Numerous evidences suggest that mirNAs can act as tumor suppressive or oncogenes and can be incorporated into novel cancer therapies. Performing comprehensive and well-designed, retrospective and prospective 
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